EXCHANGE TRADED CONCEPTS, LLC
Position in DNA — Ginkgo Bioworks Holdings, Inc.
CIK 1457320
OKLAHOMA CITY, OK
Position in DNA
as of Mar 31, 2026
· filed Apr 15, 2026
Position Value
$1,973,627
-$933,152 QoQ
Shares Held
321,962
-8.0% QoQ
Ownership
0.493%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in DNA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026EXCHANGE TRADED CONCEPTS, LLC holds $43,501,968 across 34 Biotechnology names. DNA ranks #8 (4.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
13,875 | $6,195,741 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
5,806 | $4,485,946 | |
| 3 | INVA |
Innoviva, Inc.
|
161,248 | $3,757,078 | |
| 4 | VKTX |
Viking Therapeutics, Inc.
|
83,569 | $2,719,335 | |
| 5 | IONS |
Ionis Pharmaceuticals Inc
|
33,941 | $2,548,629 | |
| 6 | PTGX |
Protagonist Therapeutics, Inc
|
23,773 | $2,505,674 | |
| 7 | HRMY |
Harmony Biosciences Holdings, Inc.
|
87,012 | $2,437,205 | |
| 8 | DNA |
Ginkgo Bioworks Holdings, Inc.
This page
|
321,962 | $1,973,627 |
All Filings in DNA
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,973,627 | 321,962 | Shares | Sole | 2026-04-15 | |
| 2025-12-31 | $2,906,779 | 349,793 | Shares | Sole | 2026-01-14 | |
| 2025-09-30 | $4,843,009 | 332,168 | Shares | Sole | 2025-10-14 | |
| 2025-06-30 | $3,324,228 | 295,487 | Shares | Sole | 2025-07-10 | |
| 2025-03-31 | $1,777,522 | 311,846 | Shares | Sole | 2025-04-17 | |
| 2024-12-31 | $1,878,310 | 191,274 | Shares | Sole | 2025-01-21 | |
| 2024-09-30 | $2,990,870 | 366,978 | Shares | Sole | 2024-10-10 | |
| No filing history on record for this holder in this stock. | ||||||